DK2471904T3 - Placenta stem cell populations - Google Patents

Info

Publication number

DK2471904T3

DK2471904T3 DK12150919.4T DK12150919T DK2471904T3 DK 2471904 T3 DK2471904 T3 DK 2471904T3 DK 12150919 T DK12150919 T DK 12150919T DK 2471904 T3 DK2471904 T3 DK 2471904T3

Authority

DK

Denmark

Prior art keywords

cells

stem cells

placental

cell

population

Prior art date

2005-12-29

Links

• Espacenet
• Global Dossier
• Discuss

• 210000000130 stem cell Anatomy 0.000 title claims description 608
• 210000002826 placenta Anatomy 0.000 title description 117
• 210000004027 cell Anatomy 0.000 claims description 853
• 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 claims description 144
• 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims description 144
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 142
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 142
• 102100037241 Endoglin Human genes 0.000 claims description 116
• 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 116
• 238000000034 method Methods 0.000 claims description 115
• 239000000203 mixture Substances 0.000 claims description 74
• 239000002609 medium Substances 0.000 claims description 64
• 102000003729 Neprilysin Human genes 0.000 claims description 48
• 108090000028 Neprilysin Proteins 0.000 claims description 48
• 210000001185 bone marrow Anatomy 0.000 claims description 47
• 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 44
• 210000004700 fetal blood Anatomy 0.000 claims description 39
• 230000001464 adherent effect Effects 0.000 claims description 37
• 230000008774 maternal effect Effects 0.000 claims description 37
• 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 35
• 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 35
• 108091006628 SLC12A8 Proteins 0.000 claims description 27
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 26
• 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 21
• 210000002966 serum Anatomy 0.000 claims description 20
• 238000004519 manufacturing process Methods 0.000 claims description 15
• 229960003957 dexamethasone Drugs 0.000 claims description 14
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 14
• 238000010186 staining Methods 0.000 claims description 13
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 12
• MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 claims description 11
• DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 claims description 10
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 10
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 10
• 101800003838 Epidermal growth factor Proteins 0.000 claims description 9
• 230000002648 chondrogenic effect Effects 0.000 claims description 9
• 229940116977 epidermal growth factor Drugs 0.000 claims description 9
• 210000002569 neuron Anatomy 0.000 claims description 9
• 239000012894 fetal calf serum Substances 0.000 claims description 8
• 229910052711 selenium Inorganic materials 0.000 claims description 8
• 239000011669 selenium Substances 0.000 claims description 8
• 229940098773 bovine serum albumin Drugs 0.000 claims description 7
• 238000003757 reverse transcription PCR Methods 0.000 claims description 7
• 210000005009 osteogenic cell Anatomy 0.000 claims description 6
• 239000003102 growth factor Substances 0.000 claims description 5
• 238000001990 intravenous administration Methods 0.000 claims description 5
• 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 4
• 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 4
• 108020004999 messenger RNA Proteins 0.000 claims description 3
• 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
• 230000009466 transformation Effects 0.000 claims 1
• 210000004991 placental stem cell Anatomy 0.000 description 530
• 230000003169 placental effect Effects 0.000 description 207
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 134
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 134
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 129
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 129
• 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 108
• 108010024164 HLA-G Antigens Proteins 0.000 description 108
• 102100022464 5'-nucleotidase Human genes 0.000 description 95
• 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 95
• 230000010412 perfusion Effects 0.000 description 81
• 230000014509 gene expression Effects 0.000 description 67
• 230000015572 biosynthetic process Effects 0.000 description 66
• 239000000243 solution Substances 0.000 description 60
• 210000003954 umbilical cord Anatomy 0.000 description 59
• 210000001691 amnion Anatomy 0.000 description 56
• 210000001519 tissue Anatomy 0.000 description 54
• 108090000623 proteins and genes Proteins 0.000 description 53
• -1 COL-4A1 Proteins 0.000 description 47
• 210000001136 chorion Anatomy 0.000 description 45
• 150000001875 compounds Chemical class 0.000 description 45
• 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 44
• 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 44
• 102100032912 CD44 antigen Human genes 0.000 description 37
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 37
• 239000003550 marker Substances 0.000 description 37
• 230000004069 differentiation Effects 0.000 description 36
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 29
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 29
• 102100022749 Aminopeptidase N Human genes 0.000 description 28
• 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 28
• 210000005059 placental tissue Anatomy 0.000 description 28
• 239000001963 growth medium Substances 0.000 description 27
• 239000000758 substrate Substances 0.000 description 25
• 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 23
• 102100040120 Prominin-1 Human genes 0.000 description 23
• 230000001605 fetal effect Effects 0.000 description 23
• 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 20
• 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 20
• 102000004190 Enzymes Human genes 0.000 description 19
• 108090000790 Enzymes Proteins 0.000 description 19
• 229940088598 enzyme Drugs 0.000 description 19
• 239000011159 matrix material Substances 0.000 description 19
• 239000002953 phosphate buffered saline Substances 0.000 description 19
• 108010067306 Fibronectins Proteins 0.000 description 18
• 102000016359 Fibronectins Human genes 0.000 description 18
• 102100036751 Solute carrier family 12 member 8 Human genes 0.000 description 18
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 18
• 229920003023 plastic Polymers 0.000 description 18
• 239000004033 plastic Substances 0.000 description 18
• 210000004369 blood Anatomy 0.000 description 17
• 239000008280 blood Substances 0.000 description 17
• 230000006862 enzymatic digestion Effects 0.000 description 17
• 210000004993 mammalian placenta Anatomy 0.000 description 17
• 230000035755 proliferation Effects 0.000 description 17
• 238000004113 cell culture Methods 0.000 description 16
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
• 230000000694 effects Effects 0.000 description 16
• 210000003606 umbilical vein Anatomy 0.000 description 16
• 102000004169 proteins and genes Human genes 0.000 description 15
• 238000003556 assay Methods 0.000 description 14
• 230000029087 digestion Effects 0.000 description 14
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
• 239000000463 material Substances 0.000 description 14
• 210000000056 organ Anatomy 0.000 description 14
• 210000001644 umbilical artery Anatomy 0.000 description 14
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 13
• 239000012091 fetal bovine serum Substances 0.000 description 13
• 239000008188 pellet Substances 0.000 description 13
• 230000035899 viability Effects 0.000 description 13
• 102100035140 Vitronectin Human genes 0.000 description 12
• 230000006698 induction Effects 0.000 description 12
• 238000002955 isolation Methods 0.000 description 12
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
• 108060005980 Collagenase Proteins 0.000 description 11
• 102000029816 Collagenase Human genes 0.000 description 11
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
• 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 11
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 11
• 108090000631 Trypsin Proteins 0.000 description 11
• 102000004142 Trypsin Human genes 0.000 description 11
• 239000003636 conditioned culture medium Substances 0.000 description 11
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 11
• 239000008194 pharmaceutical composition Substances 0.000 description 11
• 239000012588 trypsin Substances 0.000 description 11
• 102100022454 Actin, gamma-enteric smooth muscle Human genes 0.000 description 10
• 102100029229 Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 Human genes 0.000 description 10
• 108091007065 BIRCs Proteins 0.000 description 10
• 102100027386 Beta-1,4-galactosyltransferase 6 Human genes 0.000 description 10
• 102100030621 Carboxypeptidase A4 Human genes 0.000 description 10
• 102100032404 Cholinesterase Human genes 0.000 description 10
• 102100033781 Collagen alpha-2(IV) chain Human genes 0.000 description 10
• 102100037709 Desmocollin-3 Human genes 0.000 description 10
• 102100034578 Desmoglein-2 Human genes 0.000 description 10
• 102100032050 Elongation of very long chain fatty acids protein 2 Human genes 0.000 description 10
• 102100021598 Endoplasmic reticulum aminopeptidase 1 Human genes 0.000 description 10
• 101710168245 Endoplasmic reticulum aminopeptidase 1 Proteins 0.000 description 10
• 102100021597 Endoplasmic reticulum aminopeptidase 2 Human genes 0.000 description 10
• 102100031375 Endothelial lipase Human genes 0.000 description 10
• 102100032523 G-protein coupled receptor family C group 5 member B Human genes 0.000 description 10
• 101000678433 Homo sapiens Actin, gamma-enteric smooth muscle Proteins 0.000 description 10
• 101000937502 Homo sapiens Beta-1,4-galactosyltransferase 6 Proteins 0.000 description 10
• 101000772572 Homo sapiens Carboxypeptidase A4 Proteins 0.000 description 10
• 101000943274 Homo sapiens Cholinesterase Proteins 0.000 description 10
• 101000710876 Homo sapiens Collagen alpha-2(IV) chain Proteins 0.000 description 10
• 101000968042 Homo sapiens Desmocollin-2 Proteins 0.000 description 10
• 101000880960 Homo sapiens Desmocollin-3 Proteins 0.000 description 10
• 101000924314 Homo sapiens Desmoglein-2 Proteins 0.000 description 10
• 101000921368 Homo sapiens Elongation of very long chain fatty acids protein 2 Proteins 0.000 description 10
• 101000941275 Homo sapiens Endothelial lipase Proteins 0.000 description 10
• 101001014684 Homo sapiens G-protein coupled receptor family C group 5 member B Proteins 0.000 description 10
• 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 description 10
• 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 10
• 101000629400 Homo sapiens Mesoderm-specific transcript homolog protein Proteins 0.000 description 10
• 101000970023 Homo sapiens NUAK family SNF1-like kinase 1 Proteins 0.000 description 10
• 101000588303 Homo sapiens Nuclear factor erythroid 2-related factor 3 Proteins 0.000 description 10
• 101000988401 Homo sapiens PDZ and LIM domain protein 3 Proteins 0.000 description 10
• 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 description 10
• 101000735377 Homo sapiens Protocadherin-7 Proteins 0.000 description 10
• 101000999079 Homo sapiens Radiation-inducible immediate-early gene IEX-1 Proteins 0.000 description 10
• 101000823237 Homo sapiens Reticulon-1 Proteins 0.000 description 10
• 101000836075 Homo sapiens Serpin B9 Proteins 0.000 description 10
• 101000800546 Homo sapiens Transcription factor 21 Proteins 0.000 description 10
• 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 description 10
• 101000635958 Homo sapiens Transforming growth factor beta-2 proprotein Proteins 0.000 description 10
• 101000836755 Homo sapiens Type 2 lactosamine alpha-2,3-sialyltransferase Proteins 0.000 description 10
• 101000803709 Homo sapiens Vitronectin Proteins 0.000 description 10
• 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 10
• 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 10
• 102000003810 Interleukin-18 Human genes 0.000 description 10
• 108090000171 Interleukin-18 Proteins 0.000 description 10
• 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 10
• 108010072582 Matrilin Proteins Proteins 0.000 description 10
• 102000055008 Matrilin Proteins Human genes 0.000 description 10
• 102100026821 Mesoderm-specific transcript homolog protein Human genes 0.000 description 10
• 102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 description 10
• 102100031700 Nuclear factor erythroid 2-related factor 3 Human genes 0.000 description 10
• 102100029177 PDZ and LIM domain protein 3 Human genes 0.000 description 10
• 108010004729 Phycoerythrin Proteins 0.000 description 10
• 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 10
• 102100034941 Protocadherin-7 Human genes 0.000 description 10
• 102100036900 Radiation-inducible immediate-early gene IEX-1 Human genes 0.000 description 10
• 102100022647 Reticulon-1 Human genes 0.000 description 10
• 108010069296 ST6GalNAc V brain-specific GD1alpha synthase Proteins 0.000 description 10
• 102100025517 Serpin B9 Human genes 0.000 description 10
• 102100033121 Transcription factor 21 Human genes 0.000 description 10
• 102100021382 Transcription factor GATA-6 Human genes 0.000 description 10
• 102100030737 Transforming growth factor beta-2 proprotein Human genes 0.000 description 10
• 102100027107 Type 2 lactosamine alpha-2,3-sialyltransferase Human genes 0.000 description 10
• 239000012620 biological material Substances 0.000 description 10
• 229960002424 collagenase Drugs 0.000 description 10
• 108010080821 leucine-rich amelogenin peptide Proteins 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 102100040023 Adhesion G-protein coupled receptor G6 Human genes 0.000 description 9
• 102100038191 Double-stranded RNA-specific editase 1 Human genes 0.000 description 9
• 102100024108 Dystrophin Human genes 0.000 description 9
• 102100023882 Endoribonuclease ZC3H12A Human genes 0.000 description 9
• 101000959602 Homo sapiens Adhesion G-protein coupled receptor G6 Proteins 0.000 description 9
• 101000742223 Homo sapiens Double-stranded RNA-specific editase 1 Proteins 0.000 description 9
• 101001053946 Homo sapiens Dystrophin Proteins 0.000 description 9
• 101000976212 Homo sapiens Endoribonuclease ZC3H12A Proteins 0.000 description 9
• 101000582994 Homo sapiens Myelin regulatory factor Proteins 0.000 description 9
• 101001094807 Homo sapiens Paraneoplastic antigen-like protein 8A Proteins 0.000 description 9
• 102000004889 Interleukin-6 Human genes 0.000 description 9
• 108090001005 Interleukin-6 Proteins 0.000 description 9
• 102100030372 Myelin regulatory factor Human genes 0.000 description 9
• 102100035458 Paraneoplastic antigen-like protein 8A Human genes 0.000 description 9
• 101001053942 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Diphosphomevalonate decarboxylase Proteins 0.000 description 9
• 238000005119 centrifugation Methods 0.000 description 9
• 239000012530 fluid Substances 0.000 description 9
• 230000012010 growth Effects 0.000 description 9
• 238000011084 recovery Methods 0.000 description 9
• TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 9
• 238000011282 treatment Methods 0.000 description 9
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 9
• 102100032040 Amphoterin-induced protein 2 Human genes 0.000 description 8
• 108010035532 Collagen Proteins 0.000 description 8
• 102000008186 Collagen Human genes 0.000 description 8
• 102100022145 Collagen alpha-1(IV) chain Human genes 0.000 description 8
• 102400001368 Epidermal growth factor Human genes 0.000 description 8
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 8
• 101000776165 Homo sapiens Amphoterin-induced protein 2 Proteins 0.000 description 8
• 101000901150 Homo sapiens Collagen alpha-1(IV) chain Proteins 0.000 description 8
• 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 8
• 101000583179 Homo sapiens Plakophilin-2 Proteins 0.000 description 8
• 102100020881 Interleukin-1 alpha Human genes 0.000 description 8
• 108010085895 Laminin Proteins 0.000 description 8
• 102000007547 Laminin Human genes 0.000 description 8
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 8
• 102100030348 Plakophilin-2 Human genes 0.000 description 8
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
• 229920001436 collagen Polymers 0.000 description 8
• 238000001514 detection method Methods 0.000 description 8
• 201000010099 disease Diseases 0.000 description 8
• 210000002950 fibroblast Anatomy 0.000 description 8
• 208000014674 injury Diseases 0.000 description 8
• 239000007788 liquid Substances 0.000 description 8
• 238000000926 separation method Methods 0.000 description 8
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
• 108090001061 Insulin Proteins 0.000 description 7
• 102000004877 Insulin Human genes 0.000 description 7
• 102000011782 Keratins Human genes 0.000 description 7
• 108010076876 Keratins Proteins 0.000 description 7
• 239000003146 anticoagulant agent Substances 0.000 description 7
• 239000011324 bead Substances 0.000 description 7
• 208000035475 disorder Diseases 0.000 description 7
• 238000000684 flow cytometry Methods 0.000 description 7
• 230000003394 haemopoietic effect Effects 0.000 description 7
• 229920000669 heparin Polymers 0.000 description 7
• 238000001727 in vivo Methods 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 229940125396 insulin Drugs 0.000 description 7
• 239000000523 sample Substances 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 6
• 206010021143 Hypoxia Diseases 0.000 description 6
• 229930182555 Penicillin Natural products 0.000 description 6
• 239000004698 Polyethylene Substances 0.000 description 6
• 239000004098 Tetracycline Substances 0.000 description 6
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 6
• 239000002458 cell surface marker Substances 0.000 description 6
• 238000005138 cryopreservation Methods 0.000 description 6
• 239000012595 freezing medium Substances 0.000 description 6
• 239000002874 hemostatic agent Substances 0.000 description 6
• 229960002897 heparin Drugs 0.000 description 6
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
• 239000000017 hydrogel Substances 0.000 description 6
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
• 239000003112 inhibitor Substances 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 239000002245 particle Substances 0.000 description 6
• 229940049954 penicillin Drugs 0.000 description 6
• 229920000642 polymer Polymers 0.000 description 6
• 229960005322 streptomycin Drugs 0.000 description 6
• 229960002180 tetracycline Drugs 0.000 description 6
• 229930101283 tetracycline Natural products 0.000 description 6
• 235000019364 tetracycline Nutrition 0.000 description 6
• 150000003522 tetracyclines Chemical class 0.000 description 6
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
• 229940088872 Apoptosis inhibitor Drugs 0.000 description 5
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
• 108010090804 Streptavidin Proteins 0.000 description 5
• 230000011759 adipose tissue development Effects 0.000 description 5
• 108010004469 allophycocyanin Proteins 0.000 description 5
• 208000007502 anemia Diseases 0.000 description 5
• 229940127219 anticoagulant drug Drugs 0.000 description 5
• 239000000158 apoptosis inhibitor Substances 0.000 description 5
• 230000003115 biocidal effect Effects 0.000 description 5
• 210000000988 bone and bone Anatomy 0.000 description 5
• 210000000845 cartilage Anatomy 0.000 description 5
• 230000022159 cartilage development Effects 0.000 description 5
• 230000010261 cell growth Effects 0.000 description 5
• 230000006378 damage Effects 0.000 description 5
• 230000007717 exclusion Effects 0.000 description 5
• 239000008103 glucose Substances 0.000 description 5
• 230000001146 hypoxic effect Effects 0.000 description 5
• 239000010410 layer Substances 0.000 description 5
• 239000006228 supernatant Substances 0.000 description 5
• 230000008733 trauma Effects 0.000 description 5
• 210000005166 vasculature Anatomy 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 4
• 239000004255 Butylated hydroxyanisole Substances 0.000 description 4
• OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
• 229920001917 Ficoll Polymers 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• 229920002683 Glycosaminoglycan Polymers 0.000 description 4
• 102000006354 HLA-DR Antigens Human genes 0.000 description 4
• 108010058597 HLA-DR Antigens Proteins 0.000 description 4
• 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 4
• 102100025304 Integrin beta-1 Human genes 0.000 description 4
• 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 4
• 101710128836 Large T antigen Proteins 0.000 description 4
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
• 229920000954 Polyglycolide Polymers 0.000 description 4
• 239000004365 Protease Substances 0.000 description 4
• 102000012479 Serine Proteases Human genes 0.000 description 4
• 108010022999 Serine Proteases Proteins 0.000 description 4
• 102000040945 Transcription factor Human genes 0.000 description 4
• 108091023040 Transcription factor Proteins 0.000 description 4
• 230000002378 acidificating effect Effects 0.000 description 4
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
• 230000030741 antigen processing and presentation Effects 0.000 description 4
• 210000001367 artery Anatomy 0.000 description 4
• 235000010323 ascorbic acid Nutrition 0.000 description 4
• 239000011668 ascorbic acid Substances 0.000 description 4
• 229960005070 ascorbic acid Drugs 0.000 description 4
• 229940043253 butylated hydroxyanisole Drugs 0.000 description 4
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 4
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 4
• 230000003833 cell viability Effects 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 238000012512 characterization method Methods 0.000 description 4
• 229920001577 copolymer Polymers 0.000 description 4
• 108010007093 dispase Proteins 0.000 description 4
• 239000003814 drug Substances 0.000 description 4
• 230000002500 effect on skin Effects 0.000 description 4
• 230000003511 endothelial effect Effects 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
• 239000006260 foam Substances 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 229940014259 gelatin Drugs 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
• 230000005484 gravity Effects 0.000 description 4
• 230000003659 hair regrowth Effects 0.000 description 4
• 238000002826 magnetic-activated cell sorting Methods 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 230000000877 morphologic effect Effects 0.000 description 4
• 230000004031 neuronal differentiation Effects 0.000 description 4
• 230000002572 peristaltic effect Effects 0.000 description 4
• 230000008439 repair process Effects 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 238000003860 storage Methods 0.000 description 4
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
• 210000003462 vein Anatomy 0.000 description 4
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
• YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 3
• 108700012813 7-aminoactinomycin D Proteins 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 208000032467 Aplastic anaemia Diseases 0.000 description 3
• 108090000145 Bacillolysin Proteins 0.000 description 3
• 108010081589 Becaplermin Proteins 0.000 description 3
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
• 108010053770 Deoxyribonucleases Proteins 0.000 description 3
• 102000016911 Deoxyribonucleases Human genes 0.000 description 3
• 241000283073 Equus caballus Species 0.000 description 3
• 206010015719 Exsanguination Diseases 0.000 description 3
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
• 229930182566 Gentamicin Natural products 0.000 description 3
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 108010075704 HLA-A Antigens Proteins 0.000 description 3
• 101100395310 Homo sapiens HLA-A gene Proteins 0.000 description 3
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 3
• 108010003272 Hyaluronate lyase Proteins 0.000 description 3
• 102000001974 Hyaluronidases Human genes 0.000 description 3
• 229920001612 Hydroxyethyl starch Polymers 0.000 description 3
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 3
• 239000012825 JNK inhibitor Substances 0.000 description 3
• 229940118135 JNK inhibitor Drugs 0.000 description 3
• 208000028226 Krabbe disease Diseases 0.000 description 3
• 108010052285 Membrane Proteins Proteins 0.000 description 3
• 102000005741 Metalloproteases Human genes 0.000 description 3
• 108010006035 Metalloproteases Proteins 0.000 description 3
• 206010028851 Necrosis Diseases 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• 102000035092 Neutral proteases Human genes 0.000 description 3
• 108091005507 Neutral proteases Proteins 0.000 description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 108010067372 Pancreatic elastase Proteins 0.000 description 3
• 102000016387 Pancreatic elastase Human genes 0.000 description 3
• 102000035195 Peptidases Human genes 0.000 description 3
• 108091005804 Peptidases Proteins 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 208000007536 Thrombosis Diseases 0.000 description 3
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
• 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 3
• 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 3
• 229960005305 adenosine Drugs 0.000 description 3
• 229960002576 amiloride Drugs 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 239000012131 assay buffer Substances 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 102000015736 beta 2-Microglobulin Human genes 0.000 description 3
• 108010081355 beta 2-Microglobulin Proteins 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 230000000747 cardiac effect Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• 210000001612 chondrocyte Anatomy 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 210000002744 extracellular matrix Anatomy 0.000 description 3
• 229960002518 gentamicin Drugs 0.000 description 3
• 210000002064 heart cell Anatomy 0.000 description 3
• 201000005787 hematologic cancer Diseases 0.000 description 3
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
• 229960002773 hyaluronidase Drugs 0.000 description 3
• 229960000890 hydrocortisone Drugs 0.000 description 3
• 230000005847 immunogenicity Effects 0.000 description 3
• 229960000905 indomethacin Drugs 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 230000017074 necrotic cell death Effects 0.000 description 3
• 230000001537 neural effect Effects 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 244000052769 pathogen Species 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• 238000007747 plating Methods 0.000 description 3
• 238000004321 preservation Methods 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• 230000000717 retained effect Effects 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 230000035882 stress Effects 0.000 description 3
• 239000013589 supplement Substances 0.000 description 3
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 210000002993 trophoblast Anatomy 0.000 description 3
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
• SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
• VZEZONWRBFJJMZ-UHFFFAOYSA-N 3-allyl-2-[2-(diethylamino)ethoxy]benzaldehyde Chemical compound CCN(CC)CCOC1=C(CC=C)C=CC=C1C=O VZEZONWRBFJJMZ-UHFFFAOYSA-N 0.000 description 2
• 241000270728 Alligator Species 0.000 description 2
• 201000004384 Alopecia Diseases 0.000 description 2
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
• 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
• 102400001282 Atrial natriuretic peptide Human genes 0.000 description 2
• 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
• 229940123169 Caspase inhibitor Drugs 0.000 description 2
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
• 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 2
• SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
• 102000003951 Erythropoietin Human genes 0.000 description 2
• 108090000394 Erythropoietin Proteins 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
• RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
• 241000701806 Human papillomavirus Species 0.000 description 2
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
• 239000002211 L-ascorbic acid Substances 0.000 description 2
• 235000000069 L-ascorbic acid Nutrition 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
• 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
• 108010052014 Liberase Proteins 0.000 description 2
• 102000018697 Membrane Proteins Human genes 0.000 description 2
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 2
• CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
• 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 2
• 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 2
• 229930193140 Neomycin Natural products 0.000 description 2
• 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
• 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 2
• 108010039918 Polylysine Proteins 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• 238000002123 RNA extraction Methods 0.000 description 2
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
• 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
• 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
• 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
• 101710101493 Viral myc transforming protein Proteins 0.000 description 2
• 108010031318 Vitronectin Proteins 0.000 description 2
• 238000011892 Von Kossa's method Methods 0.000 description 2
• 208000026589 Wolman disease Diseases 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 229960004308 acetylcysteine Drugs 0.000 description 2
• 210000001789 adipocyte Anatomy 0.000 description 2
• 230000002293 adipogenic effect Effects 0.000 description 2
• KDXHLJMVLXJXCW-UHFFFAOYSA-J alcian blue stain Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cu+2].[N-]1C(N=C2C3=CC(CSC(N(C)C)=[N+](C)C)=CC=C3C(N=C3C4=CC=C(CSC(N(C)C)=[N+](C)C)C=C4C(=N4)[N-]3)=N2)=C(C=C(CSC(N(C)C)=[N+](C)C)C=C2)C2=C1N=C1C2=CC(CSC(N(C)C)=[N+](C)C)=CC=C2C4=N1 KDXHLJMVLXJXCW-UHFFFAOYSA-J 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
• 229960003942 amphotericin b Drugs 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 229940072107 ascorbate Drugs 0.000 description 2
• 238000003149 assay kit Methods 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 239000007640 basal medium Substances 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
• 239000002771 cell marker Substances 0.000 description 2
• 229910010293 ceramic material Inorganic materials 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 208000016532 chronic granulomatous disease Diseases 0.000 description 2
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 238000003501 co-culture Methods 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
• 230000001332 colony forming effect Effects 0.000 description 2
• 239000002131 composite material Substances 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• 230000001186 cumulative effect Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 238000002224 dissection Methods 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 229940105423 erythropoietin Drugs 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 201000008049 fucosidosis Diseases 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 210000001654 germ layer Anatomy 0.000 description 2
• 229960003180 glutathione Drugs 0.000 description 2
• 235000003969 glutathione Nutrition 0.000 description 2
• 150000004676 glycans Chemical class 0.000 description 2
• 208000007345 glycogen storage disease Diseases 0.000 description 2
• 210000004209 hair Anatomy 0.000 description 2
• 208000018706 hematopoietic system disease Diseases 0.000 description 2
• 210000003897 hepatic stem cell Anatomy 0.000 description 2
• 229920002674 hyaluronan Polymers 0.000 description 2
• 229960003160 hyaluronic acid Drugs 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 229940050526 hydroxyethylstarch Drugs 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000006058 immune tolerance Effects 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
• 235000019341 magnesium sulphate Nutrition 0.000 description 2
• 238000013411 master cell bank Methods 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 208000030159 metabolic disease Diseases 0.000 description 2
• 210000005087 mononuclear cell Anatomy 0.000 description 2
• 201000006938 muscular dystrophy Diseases 0.000 description 2
• 210000004165 myocardium Anatomy 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 229960004927 neomycin Drugs 0.000 description 2
• 230000001272 neurogenic effect Effects 0.000 description 2
• 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 2
• 238000010899 nucleation Methods 0.000 description 2
• 229960003104 ornithine Drugs 0.000 description 2
• 230000003256 osteocytic effect Effects 0.000 description 2
• 230000002188 osteogenic effect Effects 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
• 229920002627 poly(phosphazenes) Polymers 0.000 description 2
• 229920000656 polylysine Polymers 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000035935 pregnancy Effects 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 238000009256 replacement therapy Methods 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 208000007056 sickle cell anemia Diseases 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 2
• 210000001988 somatic stem cell Anatomy 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 229920002994 synthetic fiber Polymers 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 238000010257 thawing Methods 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• 229960000187 tissue plasminogen activator Drugs 0.000 description 2
• 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 229960002647 warfarin sodium Drugs 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 1
• WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
• JCAULFRGWRHHIG-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-henicosafluorodecane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br JCAULFRGWRHHIG-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
• GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
• LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
• GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
• RXMUPNVSYKGKMY-UHFFFAOYSA-N 3-amino-6-chloro-n-(diaminomethylidene)-5-(dimethylamino)pyrazine-2-carboxamide Chemical compound CN(C)C1=NC(N)=C(C(=O)N=C(N)N)N=C1Cl RXMUPNVSYKGKMY-UHFFFAOYSA-N 0.000 description 1
• UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
• 102100033051 40S ribosomal protein S19 Human genes 0.000 description 1
• RQQJJXVETXFINY-UHFFFAOYSA-N 5-(N,N-hexamethylene)amiloride Chemical compound N1=C(N)C(C(=O)N=C(N)N)=NC(Cl)=C1N1CCCCCC1 RQQJJXVETXFINY-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• AAZMHPMNAVEBRE-SDBHATRESA-N 8-(4-chlorophenylthio)-cAMP Chemical compound N=1C=2C(N)=NC=NC=2N([C@H]2[C@@H]([C@@H]3OP(O)(=O)OC[C@H]3O2)O)C=1SC1=CC=C(Cl)C=C1 AAZMHPMNAVEBRE-SDBHATRESA-N 0.000 description 1
• 101150106774 9 gene Proteins 0.000 description 1
• GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
• 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
• 206010000383 Accidental poisoning Diseases 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
• ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
• 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
• 208000000044 Amnesia Diseases 0.000 description 1
• 239000012583 B-27 Supplement Substances 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
• 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
• 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
• 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
• 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 102100035882 Catalase Human genes 0.000 description 1
• 108010053835 Catalase Proteins 0.000 description 1
• 241000218645 Cedrus Species 0.000 description 1
• 229930186147 Cephalosporin Natural products 0.000 description 1
• 229920001287 Chondroitin sulfate Polymers 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• 108010042086 Collagen Type IV Proteins 0.000 description 1
• 102000004266 Collagen Type IV Human genes 0.000 description 1
• 206010010099 Combined immunodeficiency Diseases 0.000 description 1
• 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
• 208000025212 Constitutional neutropenia Diseases 0.000 description 1
• 101800000414 Corticotropin Proteins 0.000 description 1
• 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
• 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 229920000045 Dermatan sulfate Polymers 0.000 description 1
• 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
• 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 101100237347 Escherichia coli (strain K12) metN gene Proteins 0.000 description 1
• 208000009796 Gangliosidoses Diseases 0.000 description 1
• 208000015872 Gaucher disease Diseases 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 108010090254 Growth Differentiation Factor 5 Proteins 0.000 description 1
• 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 description 1
• 241000193159 Hathewaya histolytica Species 0.000 description 1
• 208000010496 Heart Arrest Diseases 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 208000005331 Hepatitis D Diseases 0.000 description 1
• 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
• 102000007625 Hirudins Human genes 0.000 description 1
• 108010007267 Hirudins Proteins 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
• 101001111338 Homo sapiens Neurofilament heavy polypeptide Proteins 0.000 description 1
• 206010020365 Homocystinuria Diseases 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 241000725303 Human immunodeficiency virus Species 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
• 206010052210 Infantile genetic agranulocytosis Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 108010052370 Inhibitor of Differentiation Proteins Proteins 0.000 description 1
• 102000018728 Inhibitor of Differentiation Proteins Human genes 0.000 description 1
• 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
• 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 208000012659 Joint disease Diseases 0.000 description 1
• 208000012565 Kostmann syndrome Diseases 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 208000006136 Leigh Disease Diseases 0.000 description 1
• 208000017507 Leigh syndrome Diseases 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• 102000004882 Lipase Human genes 0.000 description 1
• 239000004367 Lipase Substances 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 208000015439 Lysosomal storage disease Diseases 0.000 description 1
• JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
• 208000030162 Maple syrup disease Diseases 0.000 description 1
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
• 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
• 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
• 208000025915 Mucopolysaccharidosis type 6 Diseases 0.000 description 1
• 101100444360 Mycoplasma mycoides subsp. mycoides SC (strain PG1) ecfA1 gene Proteins 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
• 102000008730 Nestin Human genes 0.000 description 1
• 108010088225 Nestin Proteins 0.000 description 1
• 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
• 239000000006 Nitroglycerin Substances 0.000 description 1
• NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 101100464186 Oryzias latipes pkd1l1 gene Proteins 0.000 description 1
• 108090000573 Osteocalcin Proteins 0.000 description 1
• 102000004067 Osteocalcin Human genes 0.000 description 1
• 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
• 102000004264 Osteopontin Human genes 0.000 description 1
• 108010081689 Osteopontin Proteins 0.000 description 1
• 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
• 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 108010057576 Papillomavirus E7 Proteins Proteins 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 208000013234 Pearson syndrome Diseases 0.000 description 1
• 229930195708 Penicillin V Natural products 0.000 description 1
• 201000011252 Phenylketonuria Diseases 0.000 description 1
• 206010036000 Poisoning deliberate Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 241000097929 Porphyria Species 0.000 description 1
• 208000010642 Porphyrias Diseases 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• VSWDORGPIHIGNW-UHFFFAOYSA-N Pyrrolidine dithiocarbamic acid Chemical compound SC(=S)N1CCCC1 VSWDORGPIHIGNW-UHFFFAOYSA-N 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
• 108010081750 Reticulin Proteins 0.000 description 1
• 206010038997 Retroviral infections Diseases 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 206010072610 Skeletal dysplasia Diseases 0.000 description 1
• 241000191967 Staphylococcus aureus Species 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 208000022292 Tay-Sachs disease Diseases 0.000 description 1
• 229920006362 Teflon® Polymers 0.000 description 1
• 108090001109 Thermolysin Proteins 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
• QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
• 229930003268 Vitamin C Natural products 0.000 description 1
• 229930003427 Vitamin E Natural products 0.000 description 1
• 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
• 238000010317 ablation therapy Methods 0.000 description 1
• 210000005221 acidic domain Anatomy 0.000 description 1
• 229960001456 adenosine triphosphate Drugs 0.000 description 1
• 230000009815 adipogenic differentiation Effects 0.000 description 1
• 239000012574 advanced DMEM Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 229940050528 albumin Drugs 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 108010001122 alpha(2)-microglobulin Proteins 0.000 description 1
• 210000004381 amniotic fluid Anatomy 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 206010068168 androgenetic alopecia Diseases 0.000 description 1
• 229940127090 anticoagulant agent Drugs 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940127088 antihypertensive drug Drugs 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 229960004676 antithrombotic agent Drugs 0.000 description 1
• 238000003491 array Methods 0.000 description 1
• 230000003416 augmentation Effects 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 210000000721 basilar membrane Anatomy 0.000 description 1
• 238000010009 beating Methods 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 239000005312 bioglass Substances 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 208000015322 bone marrow disease Diseases 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
• 229960005263 bucladesine Drugs 0.000 description 1
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical class [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
• BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical class [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
• 235000012255 calcium oxide Nutrition 0.000 description 1
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical class [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
• 235000011132 calcium sulphate Nutrition 0.000 description 1
• 230000003185 calcium uptake Effects 0.000 description 1
• KMQAPZBMEMMKSS-UHFFFAOYSA-K calcium;magnesium;phosphate Chemical class [Mg+2].[Ca+2].[O-]P([O-])([O-])=O KMQAPZBMEMMKSS-UHFFFAOYSA-K 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 210000004413 cardiac myocyte Anatomy 0.000 description 1
• 230000001269 cardiogenic effect Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 229940105657 catalase Drugs 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 229960005361 cefaclor Drugs 0.000 description 1
• QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
• 229960004841 cefadroxil Drugs 0.000 description 1
• NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
• 229960002129 cefixime Drugs 0.000 description 1
• OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
• 229960002580 cefprozil Drugs 0.000 description 1
• 229960002588 cefradine Drugs 0.000 description 1
• 229960001668 cefuroxime Drugs 0.000 description 1
• JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
• 210000005056 cell body Anatomy 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 229940106164 cephalexin Drugs 0.000 description 1
• ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
• 229940124587 cephalosporin Drugs 0.000 description 1
• 150000001780 cephalosporins Chemical class 0.000 description 1
• RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
• 206010008129 cerebral palsy Diseases 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 231100000481 chemical toxicant Toxicity 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229930002875 chlorophyll Natural products 0.000 description 1
• 235000019804 chlorophyll Nutrition 0.000 description 1
• ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
• 230000009816 chondrogenic differentiation Effects 0.000 description 1
• 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
• KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 229960003405 ciprofloxacin Drugs 0.000 description 1
• 229960002626 clarithromycin Drugs 0.000 description 1
• AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
• 229960003120 clonazepam Drugs 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 230000003920 cognitive function Effects 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 238000004624 confocal microscopy Methods 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• 229940041967 corticotropin-releasing hormone Drugs 0.000 description 1
• KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• 238000002316 cosmetic surgery Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 210000005151 decidua basalis Anatomy 0.000 description 1
• 210000005150 decidua parietalis Anatomy 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 229940119679 deoxyribonucleases Drugs 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 229940051593 dermatan sulfate Drugs 0.000 description 1
• AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
• 229940119744 dextran 40 Drugs 0.000 description 1
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 208000016097 disease of metabolism Diseases 0.000 description 1
• XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 210000004177 elastic tissue Anatomy 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• 238000002641 enzyme replacement therapy Methods 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 229960003276 erythromycin Drugs 0.000 description 1
• QDERNBXNXJCIQK-UHFFFAOYSA-N ethylisopropylamiloride Chemical compound CCN(C(C)C)C1=NC(N)=C(C(=O)N=C(N)N)N=C1Cl QDERNBXNXJCIQK-UHFFFAOYSA-N 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 108091022862 fatty acid binding Proteins 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
• 238000011223 gene expression profiling Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 229960002743 glutamine Drugs 0.000 description 1
• 229960003711 glyceryl trinitrate Drugs 0.000 description 1
• 201000004502 glycogen storage disease II Diseases 0.000 description 1
• 210000002149 gonad Anatomy 0.000 description 1
• 230000003779 hair growth Effects 0.000 description 1
• 208000024963 hair loss Diseases 0.000 description 1
• 230000003676 hair loss Effects 0.000 description 1
• 238000012835 hanging drop method Methods 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 229960001008 heparin sodium Drugs 0.000 description 1
• 208000005252 hepatitis A Diseases 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 201000010284 hepatitis E Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 229940027278 hetastarch Drugs 0.000 description 1
• 229940006607 hirudin Drugs 0.000 description 1
• WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 229960002474 hydralazine Drugs 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 238000003365 immunocytochemistry Methods 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 208000016245 inborn errors of metabolism Diseases 0.000 description 1
• 230000001965 increasing effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 208000015978 inherited metabolic disease Diseases 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 230000037041 intracellular level Effects 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 229940099563 lactobionic acid Drugs 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 210000003041 ligament Anatomy 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 235000019421 lipase Nutrition 0.000 description 1
• 108091010042 lipase binding proteins Proteins 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000003120 macrolide antibiotic agent Substances 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 229910001425 magnesium ion Inorganic materials 0.000 description 1
• 229960003390 magnesium sulfate Drugs 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 208000024393 maple syrup urine disease Diseases 0.000 description 1
• 108010082117 matrigel Proteins 0.000 description 1
• 230000006984 memory degeneration Effects 0.000 description 1
• 208000023060 memory loss Diseases 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 230000004089 microcirculation Effects 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 229960003632 minoxidil Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 230000000921 morphogenic effect Effects 0.000 description 1
• 230000000510 mucolytic effect Effects 0.000 description 1
• 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
• 201000002273 mucopolysaccharidosis II Diseases 0.000 description 1
• 208000000690 mucopolysaccharidosis VI Diseases 0.000 description 1
• 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 210000001665 muscle stem cell Anatomy 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 230000001114 myogenic effect Effects 0.000 description 1
• 230000009707 neogenesis Effects 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 210000005055 nestin Anatomy 0.000 description 1
• 210000003061 neural cell Anatomy 0.000 description 1
• 210000001178 neural stem cell Anatomy 0.000 description 1
• 210000003757 neuroblast Anatomy 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
• 230000001453 nonthrombogenic effect Effects 0.000 description 1
• 231100000028 nontoxic concentration Toxicity 0.000 description 1
• 229960001180 norfloxacin Drugs 0.000 description 1
• OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 229960000988 nystatin Drugs 0.000 description 1
• VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
• 229960001699 ofloxacin Drugs 0.000 description 1
• 210000001706 olfactory mucosa Anatomy 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 229920000620 organic polymer Polymers 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 210000004409 osteocyte Anatomy 0.000 description 1
• 230000009818 osteogenic differentiation Effects 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 210000004738 parenchymal cell Anatomy 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229940056360 penicillin g Drugs 0.000 description 1
• 229940056367 penicillin v Drugs 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
• 229960001217 perflubron Drugs 0.000 description 1
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
• BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
• 210000005152 placental membrane Anatomy 0.000 description 1
• 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 108010055896 polyornithine Proteins 0.000 description 1
• 229920002714 polyornithine Polymers 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229920003226 polyurethane urea Polymers 0.000 description 1
• 229920002689 polyvinyl acetate Polymers 0.000 description 1
• 239000011118 polyvinyl acetate Substances 0.000 description 1
• 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 229960002816 potassium chloride Drugs 0.000 description 1
• 229960002429 proline Drugs 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• 238000003908 quality control method Methods 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
• 101150036383 rad16 gene Proteins 0.000 description 1
• MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 238000002278 reconstructive surgery Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000009711 regulatory function Effects 0.000 description 1
• 238000005067 remediation Methods 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 208000032253 retinal ischemia Diseases 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 238000011218 seed culture Methods 0.000 description 1
• 230000009758 senescence Effects 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 239000004017 serum-free culture medium Substances 0.000 description 1
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
• 208000027390 severe congenital neutropenia 3 Diseases 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 229940083618 sodium nitroprusside Drugs 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• DMRMZQATXPQOTP-GWTDSMLYSA-M sodium;(4ar,6r,7r,7as)-6-(6-amino-8-bromopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DMRMZQATXPQOTP-GWTDSMLYSA-M 0.000 description 1
• YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 108010048090 soybean lectin Proteins 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000003068 static effect Effects 0.000 description 1
• 230000023895 stem cell maintenance Effects 0.000 description 1
• 229960002385 streptomycin sulfate Drugs 0.000 description 1
• 125000000542 sulfonic acid group Chemical group 0.000 description 1
• 239000002344 surface layer Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• 101150061166 tetR gene Proteins 0.000 description 1
• GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 230000009772 tissue formation Effects 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 229960000707 tobramycin Drugs 0.000 description 1
• NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
• 235000010384 tocopherol Nutrition 0.000 description 1
• 229930003799 tocopherol Natural products 0.000 description 1
• 229960001295 tocopherol Drugs 0.000 description 1
• 239000011732 tocopherol Substances 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 230000008736 traumatic injury Effects 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
• 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
• 210000003454 tympanic membrane Anatomy 0.000 description 1
• 201000011296 tyrosinemia Diseases 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
• 229960000604 valproic acid Drugs 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 229960001722 verapamil Drugs 0.000 description 1
• 235000019154 vitamin C Nutrition 0.000 description 1
• 239000011718 vitamin C Substances 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 239000011709 vitamin E Substances 0.000 description 1
• 229940046009 vitamin E Drugs 0.000 description 1
• 238000003260 vortexing Methods 0.000 description 1
• 230000037314 wound repair Effects 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1